Novartis (NYSE: NVS) announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE